Peptide receptor radionuclide therapy (PRRT) transcriptomic signature in blood for prediction of 177lu-octreotate efficacy.
Volume: 36, Issue: 15_suppl, Pages: 4101 - 4101
Published: May 20, 2018
Abstract
4101 Background: PRRT uses somatostatin receptor (SSR) expression on neuroendocrine tumors (NET) to deliver radiotherapy. Pretreatment patient stratification for response remains a key unmet need. NET transcript expression in blood integrated with tumor grade provides a PRRT predictive quotient (PPQ). This study validates the clinical utility for PRRT. Methods: Development and validation was undertaken in 3 independent 177Lu-PRRT-cohorts....
Paper Details
Title
Peptide receptor radionuclide therapy (PRRT) transcriptomic signature in blood for prediction of 177lu-octreotate efficacy.
Published Date
May 20, 2018
Journal
Volume
36
Issue
15_suppl
Pages
4101 - 4101
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History